Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02986698 · ClinicalTrials.gov registry record · Phase 1
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02986698 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 6 participants.
The verdict
NCT02986698, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The investigators aims to evaluate the safety of in utero hematopoietic stem cell transplantation in fetuses with alpha-thalassemia major performed at the time of in utero transfusion of red blood cells.
Interventions
- BIOLOGICAL in utero hematopoietic stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02986698
The ClinicalTrials.gov registry entry for NCT02986698 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which in utero hematopoietic stem cell transplantation is the first listed.
NCT02986698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02986698 about?
NCT02986698 is a clinical study titled "In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)". The investigators aims to evaluate the safety of in utero hematopoietic stem cell transplantation in fetuses with alpha-thalassemia major performed at the time of in utero transfusion of red blood cells.
What is the current status of trial NCT02986698?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-10-05. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT02986698?
The interventions under investigation include: in utero hematopoietic stem cell transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT02986698?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.